Publisher’s latest Pharmaceutical and Healthcare disease pipeline guide Hospital Acquired Pneumonia (HAP) – Pipeline Review, H1 2019, provides an overview of the Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline landscape.
Hospital Acquired Pneumonia (HAP) is defined as pneumonia acquired during hospital stay. Symptoms include cough, fever, shaking chills, confusion, headache and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle.
Key Players:
- Aridis Pharmaceuticals Inc
- AstraZeneca Plc
- Centauri Therapeutics Ltd
- Cumberland Pharmaceuticals Inc
- CytaCoat AB
- Destiny Pharma Plc
- Dong-A Socio Holdings Co Ltd
- Evaxion Biotech ApS
- MedImmune LLC
- Meiji Seika Pharma Co Ltd
- Merck & Co Inc
- Motif Bio Plc
- Nabriva Therapeutics Plc
- Polyphor AG
- Sealife PHARMA GMBH
- Shionogi & Co Ltd
- Spero Therapeutics Inc
- Tetraphase Pharmaceuticals Inc
- Wockhardt Ltd
Get Sample Copy of this Report@ https://www.orbisresearch.com/contacts/request-sample/2663681
Report Highlights:
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Hospital Acquired Pneumonia (HAP) – Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Hospital Acquired Pneumonia (HAP) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hospital Acquired Pneumonia (HAP) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 8, 5, 10, 10, 2 and 1 respectively.
Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope:
– The pipeline guide provides a snapshot of the global therapeutic landscape of Hospital Acquired Pneumonia (HAP) (Infectious Disease).
– The pipeline guide reviews pipeline therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Hospital Acquired Pneumonia (HAP) (Infectious Disease) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Hospital Acquired Pneumonia (HAP) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease)
Make an Inquiry before Buying@ https://www.orbisresearch.com/contacts/enquiry-before-buying/2663681
Reasons to buy:
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Hospital Acquired Pneumonia (HAP) (Infectious Disease).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Points from TOC:
Introduction
Hospital Acquired Pneumonia (HAP) – Overview
Hospital Acquired Pneumonia (HAP) – Therapeutics Development
Hospital Acquired Pneumonia (HAP) – Therapeutics Assessment
Hospital Acquired Pneumonia (HAP) – Companies Involved in Therapeutics Development
Hospital Acquired Pneumonia (HAP) – Drug Profiles
Hospital Acquired Pneumonia (HAP) – Dormant Projects
Hospital Acquired Pneumonia (HAP) – Discontinued Products
Hospital Acquired Pneumonia (HAP) – Product Development Milestones
Appendix
Get More Information about this Report@ https://www.orbisresearch.com/reports/index/hospital-acquired-pneumonia-hap-pipeline-review-h1-2019
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Contact Info:
Hector Costello
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019
Email id: sales@orbisresearch.com
Your information will never be shared with any third party.